Inhibrx, Inc., also known as INBX, is a biotechnology company that specializes in the development of therapeutic antibodies. As a biotech company, it is important for investors to consider the technical analysis of INBX stock before making any investment decisions. Technical analysis involves the use of various indicators to analyze the price movement and trends of a stock. By understanding these indicators, investors can gain insights into the potential future performance of the stock.

One important technical indicator to consider is the Relative Strength Index (RSI). This indicator measures the strength and momentum of the stock by comparing the magnitude of recent gains against recent losses. A high RSI value indicates that the stock may be overbought, while a low RSI value suggests that the stock may be oversold. The RSI for INBX stock can provide valuable information about its current market conditions.

Inhibrx (INBX) Technical Analysis

Get insights on Inhibrx, Inc. (INBX) stock with technical analysis indicators such as RSI, ADX, MACD, ROC, STOCHRSI, WILLR. Discover the performance of INBX stock through comprehensive analysis. Stay informed and make informed decisions.

Inhibrx, Inc. (INBX) Technical Analysis: Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

Inhibrx

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	67.02	Neutral	76.1%
auto_graphMACD	12.69	Neutral	32.4%
auto_graphCCI	130.28	Sell	266.5%
auto_graphADX	34.86	Neutral	-33.9%
auto_graphATR	14.54	Buy	-
auto_graphWILLR	-13.18	Sell	175.4%
auto_graphROC	19.32	Neutral	45.2%
auto_graphSTOCHRSI	100.00	Sell	20.6%

Buy	1	-87.50%
Hold	4	-50.00%
Sell	3	-62.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Inhibrx (INBX) Technical Analysis

Keep an eye on Inhibrx

Frequently Asked Questions

What are the technical signals for Inhibrx (INBX) stock based on the last 30 days?

Take Your Investments to a Whole New Level